European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research
- J Avouac1,
- O Kowal-Bielecka2,
- R Landewe3,
- S Chwiesko2,
- I Miniati4,
- L Czirjak5,
- P Clements6,
- C Denton7,
- D Farge8,
- K Fligelstone9,
- I Földvari10,
- D E Furst6,
- U Müller-Ladner11,
- J Seibold12,
- R M Silver13,
- K Takehara14,
- B Garay Toth15,
- A Tyndall16,
- G Valentini17,
- F van den Hoogen18,
- F Wigley19,
- F Zulian20,
- M Matucci-Cerinic4,
- and EUSTAR coauthors
- 1Rheumatology A Department, RDU, Paris, France
- 2Rheumatology Department, Medical University, Bialystok, Poland
- 3Rheumatology Department, University Hospital, Maastricht, Netherlands
- 4Rheumatology Department, UF, Florence, Italy
- 5Rheumatology Department, University of Pecs, Pecs, Hungary
- 6Rheumatology Department, University of California Los Angeles, Los Angeles, California, USA
- 7Rheumatology Department, Royal Free Hospital, London, UK
- 8Internal Medicine Department, Hopital St Louis, Paris, France
- 9Scleroderma Association, Federation European Scleroderma Associations (FESCA), Harlesden, UK
- 10Rheumatology Department, Klinik Eilbek, Hamburg, Germany
- 11Rheumatology Department, University of Giessen, Bad Nauheim, Germany
- 12Rheumatology Department, University of Michigan, Ann Arbor, Michigan, USA
- 13Rheumatology Department, Medical University of South Carolina, Charleston, Virginia, USA
- 14Dermatology Department, University School of Medicine, Kanazawa, Japan
- 15Federation European Scleroderma Associations (FESCA), Budapest, Hungary
- 16Rheumatology Department, University Hospital, Basel, Switzerland
- 17Rheumatology Department, Second University, Naples, Italy
- 18Rheumatology Department, Radboud University Medical Center, Nijmegen, Netherlands
- 19Rheumatology Department, John Hopkins University, Baltimore, Maryland, USA
- 20Rheumatology Department, University of Padua, Padua, Italy
- M Matucci-Cerinic, Department of Biomedicine, Division of Rheumatology, University of Florence, Villa Monna Tessa, Viale G Pieraccini 18, 50134, Florence, Italy; cerinic{at}unifi.it
- Accepted 29 December 2008
- Published Online First 28 October 2008
Abstract
Objective: To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail.
Methods: In agreement with the EULAR standard operating procedures a Task Force was created that consisted of the EUSTAR board members, 10 systemic sclerosis (SSc) experts invited from outside the EUSTAR board and representing Europe, the USA and Japan, a clinical epidemiologist, 2 patients with SSc and 3 fellows for literature research. All EUSTAR centres were invited to contribute to the development of recommendations through submission and preliminary selection of the research questions. The systematic literature research was performed using the Pubmed, Medline, EMBASE and Cochrane databases. Retrieved trials were evaluated according to the Jadad classification, and the level of evidence was graded from 1 to 4. Outcome data for efficacy and adverse events were abstracted and effect size, number needed to treat (NNT) and number needed to harm (NNH) were calculated when appropriate.
Results: In all, 65 EUSTAR Centres provided 304 research questions concerning SSc treatment. These questions were aggregated, subdivided into 19 treatment categories and then subjected to preliminary selection by a web-based Delphi technique. The final set of 26 research questions was created by the Expert Committee based on the results of the Delphi exercise and the expert’s experience.
Conclusions: This paper is a comprehensive summary of the methods we used to build recommendations for the drug treatment of systemic sclerosis, combining an evidence based approach and expert opinion.
Footnotes
-
Competing interests: None declared.
-
‣ The list of EUSTAR coauthors is published online only at http://ard.bmj.com/content/vol68/issue5








